Serum Institute of India, the world’s largest vaccine producer, said it has made 40 million doses of AstraZeneca’s potential Covid-19 vaccine, and would soon begin making Novavax’s rival shot, as they both seek regulatory approval.

Serum said it had enrolled 1,600 participants in India for late-stage trials of AstraZeneca's candidate, and also plans to seek regulatory approval to run late-stage trials for the Novavax vaccine.

The AstraZeneca vaccine, co-developed by Oxford University, is the most advanced in human testing in India, Serum said, adding that the company and the Indian Council of Medical Research (ICMR) will pursue “early availability” of the shot in India.